THE WOODLANDS, Texas, July 8, 2004 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM) announces today the Company has secured the exclusive rights to their NAF Test for the early detection of breast cancer. Attaining the exclusive rights to the patents and technologies developed in collaboration with the University of Texas (UT) M.D. Anderson Cancer Center puts the Company in a strong competitive position for the commencement of its summer clinical validation trials.
The Agreement provides detection, diagnosis, and monitoring of breast cancer through proteomic analysis of nipple aspirate fluids (NAF). The fluid obtained through a non-invasive procedure utilizing a modified breast pump is collected from the breast ductal region where most breast cancers originate. When analyzed by the Company's patent pending methodology and technology the proteins in this fluid reveal specific "disease protein footprints." This breakthrough technology resulted from the joint development efforts of Power3 Medical and UT M.D. Anderson, including joint patent filings and publications.
"We have identified 130 protein biomarkers that we believe not only provide for the early detection of breast cancer but reveal the blueprint for how cancer develops. This technology holds great promise for commercialization in large markets with the potential to achieve an earlier and more accurate diagnosis of breast cancer and ultimately identify specific drug targets for earlier treatment," said Ira L. Goldknopf, Ph.D., Chief Scientific Officer of Power3 Medical.
About Power3 Medical Products
Power3 Medical Products, Inc. is a leading edge biotechnology company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases that the Company's proprietary technology can detect in patients. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company is in a strong competitive position with over 250 identified biomarkers of human disease and operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.
In addition, all current shareholders, and interested parties should sign into our private Corporate Guest Book: (www.CorporateGuestBook.com/?PWRM) to receive timely updates and information on future developments.
Safe Harbor Statement
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.